GlaxoSmithKline and Synta Pharmaceuticals collaborate on skin cancer drug
Under the terms of the agreement, the companies will share responsibility for development and commercialization of the oxidative stress inducer, STA-4783, in the US. GlaxoSmithKline (GSK) will have
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.